Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Medicinal Research Reviews Année : 2021

Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness

Tania Gamberi
  • Fonction : Auteur
Tania Fiaschi
  • Fonction : Auteur
Alessandra Modesti
  • Fonction : Auteur
Flavia Sorbi
  • Fonction : Auteur
Francesca Magherini
  • Fonction : Auteur
  • PersonId : 1139564

Résumé

Auranofin is an oral gold(I) compound, initially developed for the treatment of rheumatoid arthritis. Currently, Auranofin is under investigation for oncological application within a drug repurposing plan due to the relevant antineoplastic activity observed both in vitro and in vivo tumor models. In this review, we analysed studies in which Auranofin was used as a single drug or in combination with other molecules to enhance their anticancer activity or to overcome chemoresistance. The analysis of different targets/pathways affected by this drug in different cancer types has allowed us to highlight several Med Res Rev.
Fichier principal
Vignette du fichier
med.21872.pdf (1.85 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03461453 , version 1 (01-12-2021)

Identifiants

Citer

Tania Gamberi, Giovanni Chiappetta, Tania Fiaschi, Alessandra Modesti, Flavia Sorbi, et al.. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness. Medicinal Research Reviews, 2021, ⟨10.1002/med.21872⟩. ⟨hal-03461453⟩
35 Consultations
89 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More